Subtype
Malignant Thymus Neoplasm
CI-CAN-00001185Explore in graph →
80 active trials1 approved drugs1 evidence items
- NCIt
- C4962
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001185Explore in graph →
Clinical trials
193 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (22)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02628405 | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma | unknown | Phase 1 / Phase 2 | 30 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT03921671 | Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)(RELEVENT) | unknown | Phase 2 | 60 | Claudia ProtoOTHER | 1 | May 29, 2024 |
| clinicaltrials |
| NCT06412068 | A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment | unknown | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 0 | May 14, 2024 | clinicaltrials |
| NCT04870853 | Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy | unknown | — | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT05208853 | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma | unknown | Early Phase 1 | 9 | Zhejiang UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT03449173 | Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)(Style) | unknown | Phase 2 | 56 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04705129 | Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT04614818 | A Multi-center, Retrospective Analysis of Clinical Character, Outcome and Prognosis of Lymphoepithelioma-like Carcinoma | unknown | — | 700 | Sun Yat-sen UniversityOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT04600947 | Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma | unknown | Phase 2 | 69 | Taizhou HoudeAoke Biomedical Co., Ltd.INDUSTRY | 1 | Oct 23, 2020 | clinicaltrials |
| NCT02364076 | Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma | unknown | Phase 2 | 45 | Georgetown UniversityOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT02747732 | Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL | unknown | Phase 2 | 72 | Meirav Kedmi MDOTHER_GOV | 1 | Apr 23, 2019 | clinicaltrials |
| NCT03346642 | Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Dec 3, 2018 | clinicaltrials |
| NCT03170804 | Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer | unknown | — | 200 | Aventura Hospital and Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Jul 1, 2024source: clinicaltrials